EPI 2010

Drug Profile

EPI 2010

Alternative Names: Durason; EpiGenRx; NEU 2010

Latest Information Update: 10 Jul 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator East Carolina University
  • Developer East Carolina University; EpiGenesis Pharmaceuticals
  • Class Antiasthmatics; Antisense oligonucleotides
  • Mechanism of Action Adenosine A1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 10 Jul 2003 Discontinued - Phase-II for Asthma in United Kingdom (Inhalation)
  • 10 Jul 2003 Discontinued - Phase-II for Asthma in USA (Inhalation)
  • 31 Dec 2001 Phase-II clinical trials in Asthma in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top